Les nouveaux médicaments de l’obésité : un changement de paradigme ?
(2024) Louvain médical — Vol. 143, n° 04, p. 287-291 (2024)
Files
2024_Thissen_LM_287-291.pdf
Open Access - Adobe PDF
- 87.21 KB
Details
- Authors
Thissen, Jean-Paul 
- Abstract
- (en) [New obesity drugs: a paradigm shift?] GLP-1 receptor agonists (GLP-1RAs) are the most extensively studied drug class for obesity treatment. These molecules induce significant weight loss and an improvement regarding comorbidities associated with excess weight. Weight loss results almost exclusively from caloric intake reduction. GLP-1RAs are well tolerated and have a satisfactory safety profile. Molecules currently under development aim to enhance weight loss, notably by targeting other receptors, and to improve patient compliance. Their use raises many questions (cost and possible reimbursement, duration of use, very long-term safety, place in relation to dietary management and bariatric surgery, etc.). Even though all these questions must be addressed, a paradigm shift is taking shape in the management of obesity, after decades of failure.
- Affiliations
Citations
Thissen, J.-P. (2024). Les nouveaux médicaments de l’obésité : un changement de paradigme ? Louvain médical, 143(04), 287-291. https://hdl.handle.net/2078.5/216665 (Original work published 2024)